氯雷他定糖浆治疗小儿皮炎、湿疹疗效观察

笔者于2002年3月～2003年3月，应用氯雷他定糖浆(开瑞坦糖浆，上海先灵葆雅制药有限公司)治疗了57例小儿皮炎、湿疹患者，取得了较满意的临床疗效，现将结果报告如下.     

氯雷他定治疗慢性荨麻疹93例临床疗效观察

氯雷他定(商品名：百为坦)是目前临床上治疗各种皮炎、湿疹、荨麻疹等瘙痒性皮肤病的常用抗过敏药物。我们于2002年8月25日-9月25日，应用百为坦治疗了93例慢性荨麻疹患者，并对其疗效和安全性进行了观察，现总结报告如下。     

两种氯雷他定治疗慢性特发性荨麻疹的临床疗效观察

氯雷他定（loratadine）是一种无嗜睡作用的H1受体拮抗剂,具有良好的抗组胺和抗炎作用。为评价两种氯雷他定片剂（一种商品名为百为坦,河南三门峡赛诺维制药有限公司;另一种商品名为开瑞坦,上海先灵葆雅制药有限公司）治疗慢性特发性荨麻疹的临床效果,笔者于2003年10-12月采用多中心、开放、随机、平行对照的方法,对120例慢性特发性荨麻疹患者分别采用百为坦与开瑞坦治疗,并进行疗效对比观察,现报告如下。     

咪唑斯汀治疗皮炎湿疹68例临床分析

目的评价咪唑斯汀治疗皮炎湿疹的临床疗效。方法118例皮炎湿疹患者随机分为两组,咪唑斯汀组68例口服咪唑斯汀10mg,氯雷他定组50例口服氯雷他定10mg,均1次/d。结果咪唑斯汀治疗急慢性湿疹和异位性皮炎3周有效率为90.7%,氯雷他定组为60.0%,两组差异有显著性(P<0.01);咪唑斯汀与氯雷他定对接触性皮炎的1周有效率均为100%,差异无显著性(P>0.05)。结论咪唑斯汀是治疗皮炎湿疹等过敏性疾病的理想药物。     

氯雷他定与派瑞松联合治疗皮炎湿疹类皮肤病疗效观察

目的探究氯雷他定与派瑞松对皮炎湿疹类皮肤病的疗效。方法选择2016年8月20日~2017年8月20日至我院皮肤科就诊的皮炎湿疹类皮肤病患者共有82例,,信封随机分组模式分为两组,分别给予不同的治疗方式,将两组的治疗效果进行对比。结果治疗前实验组与常规组积分分别为(65.28±4.26)分与(65.78±4.78)分,无明显差异,P0.05,治疗后实验组积分为(95.22±3.21)分,明显高于常规组(82.14±3.36)分,P0.05;治疗总有效率:实验组为95.12%,常规组为78.05%,P0.05。结论对皮炎湿疹类皮肤病患者给予氯雷他定与派瑞松治疗,便于改善其临床症状,值得采纳。     

盐酸非索非那定联合氯雷他定治疗慢性荨麻疹疗效观察

我院于2006年3—8月通过180例慢性荨麻疹患者以随机、开放、平行对照的方法研究非索非那定（商品名：阿特拉）与氯雷他定（商品名：开瑞坦）联用治疗慢性荨麻疹的疗效与安全性，现将结果报道如下。     

地氯雷他定治疗荨麻疹的疗效观察

目的：探讨地氯雷他定治疗荨麻疹的临床疗效及其安全性。方法：对门诊符合标准的95例患采用开放平行对照的方法进行临床研究，患分成两组。分别接受地氯雷他定和氯雷他定治疗，疗程14天。结果：地氯雷他定能有效缓解慢性荨麻疹患的瘙痒症状，有效减少风团的数目与风团的直径，地氯雷他定治疗慢性荨麻疹的有效率为91．5％，氯雷他定为89．6％，治疗过程中未见严重不良反应。结论：地氯雷他定治疗慢性荨麻疹疗效可靠，安全性好，略优于氯雷他定。     

左西替利嗪、氯雷他定联合胸腺肽治疗慢性湿疹疗效观察

目的观察左西替利嗪、氯雷他定联合胸腺肽治疗慢性湿疹临床疗效。方法122例患者随机分成两组,治疗组采用胸腺肽注射液l00mg加入5％葡萄糖注射液250ml中静脉滴注,1次／d,连续2周,同时口服左西替利嗪片lOmg／d,氯雷他定片l0mg／d,连续4周;对照组单用左西替利嗪、氯雷他定,方法和疗程同治疗组。结果治疗组和对照组有效率分别为80．65％和56．67％,两组有效率比较差异有显著性（P〈0．05）。结论左西替利嗪、氯雷他定联合胸腺肽治疗慢性湿疹疗效显著。     

复方甘草酸苷联合葡萄糖酸钙治疗皮炎湿疹的疗效观察

目的观察复方甘草酸苷联合葡萄糖酸钙治疗皮炎湿疹的临床疗效。方法101例皮炎湿疹患者随机分为两组:A组69例,给予复方甘草酸苷注射液40mL,10%葡萄糖酸钙10mL、维生素C3g加入5%葡萄糖250mL静滴,1次/d,口服氯雷他定10mg,1次/d;B组32例,除不用复方甘草酸苷外,其他治疗同A组。结果A组有效率为86.96%,B组为65.63%,两组比较差异有显著性(P<0.05)。结论复方甘草酸苷联合葡萄糖酸钙治疗皮炎湿疹疗效好,无明显毒副作用,安全性高。     

湿疹及皮炎

20053103咪唑斯汀治疗皮炎湿疹68例临床分析/段民录(西安电力中心医院皮肤科)∥中国皮肤性病学杂志.-2005,19(6).-380~381随机分为两组,咪唑斯汀组68例口服咪唑斯汀10mg,氯雷他定组50例口服氯雷他定10mg,均1次/d。咪唑斯汀治疗急慢性湿疹和异位性皮炎3周有效率为90.7%,氯雷他定为60.0%。两组差异有显著性(P<0.01),咪唑斯汀与氯雷他定对接触性皮炎的1周有效率均为100%,差异无显著性(P>0.05)。表2参2(余春艳)20053104易菲莎治疗皮炎湿疹130例/周英芹(江苏建湖县疾控中心),於如军∥皮肤病与性病.-2005,27(2).-24均外用易菲莎,早晚各1次,1周为1…     

Hand eczema in patients with history of atopic manifestations in childhood

A follow-up study of two groups of individuals aged 24-44 years, with a history of severe and moderate atopic dermatitis in childhood (n = 549 and 406 respectively), showed that the most common site of atopic dermatitis was the hands. The prevalence of hand eczema in the two groups was 41% and 25% respectively. The corresponding figure for a group of 222 individuals with respiratory allergy, but not atopic dermatitis in childhood, was 5%, and for a control group (n = 199), without family or personal atopy, 4%. In all four groups the majority of the patients had mild to moderate hand eczema. The fingers were the most common site in all groups. In 69%, 55%, 36% and 12% respectively, hand eczema was found simultaneously with other eczematous manifestations. Irritants were considered by 71-96% in the four groups to aggravate the hand eczema. Contact with various food substances, particularly proteins, was regarded by 38%, 43%, 30% and 9% as an eliciting/aggravating factor. Dust was looked upon as an eliciting/aggravating factor by 25% and 20% of the individuals in the two groups with atopic dermatitis in childhood, but by no one in the control group.     

醋酸丙酸氢化可的松霜治疗湿疹的疗效观察

目的：比较醋酸丙酸氢化可的松霜(益芙可)和丁酸氢化可的松霜(来可得)治疗湿疹的疗效，并评价醋酸丙酸氢化可的松霜的安全性。方法：采用多中心、随机、研究者单盲、阳性对照、平行组比较方法，将湿疹患者随机分为两组，其中治疗组119例外用醋酸丙酸氢化可的松霜，对照组123例外用丁酸氢化可的松霜.结果：靶皮损总积分，治疗组改善83．1％，对照组改善84．8％。采用协方差分析模型统计学分析，醋酸丙酸氢化可的松霜的疗效与丁酸氢化可的松霜的疗效相当。治疗组有1例发生轻度刺激性皮炎。结论：醋酸丙酸氢化可的松霜治疗湿疹的疗效与丁酸氢化可的松霜相似，是一种安全、有效的外用皮质类固醇药物。     

0.05%地奈德乳剂治疗内源性湿疹的临床研究

目的　评价 0 .0 5 %地奈德乳剂治疗内源性湿疹包括特应性皮炎 3周的疗效和安全性。方法　入组包括特应性皮炎在内的内源性湿疹 84例 ,采用随机、双盲、基质对照、平行组对比研究 ,受试者外涂药物于受累区域 ,2次 /d ,连续治疗 3周。结果　试验组靶皮损总积分 (TSS)由治疗前 8.3 1± 1.85降至 1.19± 1.69,TSS改善 84.99% ;对照组TSS由 8.43± 1.67降至 3 .10± 2 .2 4,TSS改善 63 .5 4%。试验组与对照组靶皮损各项观察指标均得到改善 ,但试验组的改善优于对照组。总体改善评价试验组总有效率为 80 .95 % ,对照组为 5 2 .3 8% ,两组比较差异有显著性 (P <0 .0 5 )。　结论　 0 .0 5 %地奈德乳剂治疗内源性湿疹的临床治愈率、总体疗效优于基质 ,且不良反应发生率低 ,是一种安全有效的外用皮质类固醇激素。     

复方氟米松软膏与丙酸氯倍他索乳膏治疗慢性湿疹和神经性皮炎疗效对比研究

[摘要] 目的 观察奥深治疗慢性湿疹和神经性皮炎的临床疗效和不良反应。方法 151例慢性湿疹和神经性皮炎患者随机分为奥深治疗组76例（其中慢性湿疹45例，神经性皮炎31例），丙酸氯倍他索乳膏对照组75例（其中慢性湿疹43例，神经性皮炎32例），分别观察治疗后1、2、3周的临床疗效和不良反应。结果 治疗组和对照组治疗1周后的临床痊愈率分别为13.16 %和6.67%，两组比较无统计学差异（P>0.05），治疗组治疗后2、3周的临床痊愈率分别为53.95%和63.16%，对照组治疗后2、3周的临床痊愈率分别为28.00%和37.33 %，两组比较差异有统计学意义（P<0.05）；治疗组治疗后1、2、3周的临床有效率分别为43.42%，84.21%和92.11%，对照组治疗后1、2、3周的临床有效率分别为18.67 %，60.00%和69.33%，两组临床有效率比较差异均有统计学意义（P<0.05）。且未见有明显临床意义的不良反应。结论 奥深治疗慢性湿疹和神经性皮炎的疗效优于丙酸氯倍他索乳膏，无明显的不良反应，是治疗慢性湿疹和神经性皮炎较为理想药物。     

湿疹和特应性皮炎皮损处细菌定植情况及药物联合治疗的分析

目的 探讨湿疹和特应性皮炎(AD)皮损处金黄色葡萄球菌(金葡菌)及其他细菌的定植情况,评价抗菌药物与糖皮质激素联合用药的疗效。方法 采用多中心、随机、双盲试验,在筛选日及治疗后第7、14和28天对皮损评分,并在皮损和非皮损处分离细菌。试验组外用抗菌药物和糖皮质激素,对照组外用基质和糖皮质激素。结果 共入选患者327例,湿疹208例,AD119例。湿疹皮损处细菌的阳性率为70.19%,金葡菌占47.26%;非皮损部位细菌阳性率为32.69%,金葡菌占27.94%。AD皮损处细菌阳性率为74.79%,金葡菌占79.78%;非皮损部位细菌阳性率为34.45%,金葡菌占80.49%。湿疹和AD皮损部位金葡菌的定植量均高于非皮损部位(P<0.01,P<0.05),细菌的定植量与皮损的严重程度呈正相关。两组患者治疗后总体疗效无明显差异(P>0.05),但湿疹临床症状评分指数>8分者及AD评分指数>7分者,在治疗的第7天,试验组与对照组的症状评分指数改善率存在显著差异(P<0.05),在治疗的第14天和第28天,两组差异均无显著性(P>0.05)。结论 湿疹和AD患者皮损部位细菌的检出率和金葡菌的带菌率均明显增高,说明金葡菌与湿疹皮炎的关系密切,早期联用抗菌药物可提高疗效。     

Environmental contact factors in eczema and the results of patch testing Chinese patients with a modified European standard series of allergens

Environmental contact factors in eczema were investigated in China by clinical questionnaire and patch testing patients with a modified European standard series of allergens. 217 consecutive eczema patients were studied. Contact dermatitis (CD) was clinically diagnosed in 30% of the patients. Among the patients patch tested, 46 patients had clinically diagnosed allergic CD (ACD), 20 patients clinically had non-ACD (NACD) (including 16 cases of irritant contact dermatitis, 1 case of phototoxic contact reaction and 3 cases of asteatotic eczema) and 115 patients had clinically suspected ACD. 45 patients (98%) in the ACD group went on to have relevant patch test results. The most common ACD was from metals, fragrance materials, cosmetics and rubber materials. The most common contact allergens identified were nickel, fragrance mix, para-phenylenediamine (PPD), carba mix and thimerosal. No adverse reactions were observed to patch testing, except for pruritus in patch-test-positive patients. The positive rate of patch testing in ACD was much higher than that in NACD (98% versus 15%, P < 0.05, chi(2)-test). 60 (28%) patients had facial dermatitis (FD). Among these, 20 (33%) were confirmed as having ACD. 48 (22%) patients had hand dermatitis (HD). Among these, 7 (15%) were confirmed as having ACD. Fewer patients were confirmed as having ACD in the HD group than in the FD (15% versus 33%, P < 0.05, chi(2)-test). Although the difference was not significant, the total positivity rate in the HD group (55%) was lower than in the other groups. 65 (30%) patients had unclassified endogenous eczema (UEE). The total positive rate of patch testing in the UEE group (56%) was no different from that in the FD or HD groups. However, the relevance of positive patch tests was hard to determine in UEE. These results indicate that CD is common in eczema; relatively more patients with FD have ACD, while other factors, such as irritation, may play more of a role in HD. The total positive rate of patch testing in the UEE group was no different from that in the FD or HD groups, suggesting that patch testing should be stressed in UEE and the relevance of positive patch test results in UEE should be studied further. It is effective and safe to patch eczema patients with a modified European standard series of allergens in China.     

复方甘草酸铵综合治疗皮炎湿疹的疗效观察

目的观察复方甘草酸铵(康体多)综合治疗皮炎湿疹的临床疗效。方法治疗组18例给予综合治疗及静脉滴注康体多40ml,1次/d,共2周。对照组不用康体多,余同治疗组。结果治疗组有效率(88.9%)显著高于对照组(61.6%)(P<0.05)。结论康体多综合治疗皮炎湿疹具有疗效好,无明显副作用,重复用药有效等优点。     

An epidemiological comparison between hand eczema and non-hand eczema

Thirty four per cent of 2110 patients with eczema attending a contact dermatitis clinic presented with hand eczema. An epidemiological comparison was made of patients with hand eczema and non-hand eczema (defined as eczema on parts of the body other than the hands). Occupational eczema was significantly more common in the hand eczema than the non-hand eczema group (P = 0.0011). The prevalence of atopy was the same in both groups (13%). The prevalence of irritant contact dermatitis was higher in the hand eczema group (32%) than the non-hand eczema group (13%) (P less than 0.0001). The rate of allergic contact dermatitis was lower in the hand eczema group (23%) than the non-hand eczema group (39%) (P less than 0.0001). The rate of positive patch test reactions was lower in the hand eczema group (41%) than the non-hand eczema group (56%) (P less than 0.0001). Nickel sulphate (8%), cobalt chloride (3%), potassium dichromate (3%), and fragrance mix (4%) were common allergens encountered in hand eczema group. None of these allergens was specifically more prevalent in the hand eczema than the non-hand eczema group. However, the prevalence of allergy to nickel, colophony, epoxy resin and medicaments was significantly higher in the non-hand eczema group.     

糠酸莫米松乳膏治疗湿疹皮炎类皮肤病多中心临床研究

目的 评价0.1%糠酸莫米松乳膏治疗湿疹皮炎类皮肤病疗效和安全性。方法 本研究采用随机、双盲、平行对照的临床研究方法。受试者分别接受国产糠酸莫米松乳膏和艾洛松治疗。患者每日局部涂药1次,连续用药4周。在治疗始及治疗后第1～4周对各观察指标进行评估记录。结果 本研究共入选受试者284例(试验组和对照组各142例)中湿疹143例,神经性皮炎141例。治疗后1～4周,两组患者各项症状/体征指标计分及总计分均有明显下降。试验组和对照组组间比较差异无统计学意义。治疗结束时,湿疹患者试验组基愈率和总有效率分别为78.87%、97.18%;对照组基愈率和总有效率分别为84.51%、92.96%。神经性皮炎患者试验组基愈率和有效率分别为75.71%、100%;对照组基愈率和总有效率分别为80.28%、94.37%。两组患者总体评价试验组基愈率77.30%,有效率98.58%。对照组基愈率82.39%,有效率93.64%。两组间疗效比较差异无统计学意义。研究中两组均未发生不良反应。试验组发生接触性皮炎1例。结论 0.1%糠酸莫米松乳膏治疗湿疹、神经性皮炎使用方便,安全性好。